Summit Therapeutics (SMMT) Competitors $24.34 +1.73 (+7.63%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$24.39 +0.05 (+0.18%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMMT vs. TAK, ARGX, ONC, BNTX, TEVA, ITCI, GMAB, RDY, ASND, and VTRSShould you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Summit Therapeutics vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Summit Therapeutics (NASDAQ:SMMT) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership. Do analysts recommend SMMT or TAK? Summit Therapeutics presently has a consensus price target of $34.67, suggesting a potential upside of 42.40%. Given Summit Therapeutics' higher probable upside, equities analysts plainly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, SMMT or TAK? Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit TherapeuticsN/AN/A-$221.32M-$0.34-71.60Takeda Pharmaceutical$30.09B1.64$712.33M$0.2270.68 Does the media favor SMMT or TAK? In the previous week, Summit Therapeutics had 20 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 22 mentions for Summit Therapeutics and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.67 beat Summit Therapeutics' score of 0.57 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SMMT or TAK more profitable? Takeda Pharmaceutical has a net margin of 2.36% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 10.64% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -62.87% -51.61% Takeda Pharmaceutical 2.36%10.64%5.14% Which has more risk and volatility, SMMT or TAK? Summit Therapeutics has a beta of -1.01, indicating that its share price is 201% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Do insiders and institutionals hold more shares of SMMT or TAK? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryTakeda Pharmaceutical beats Summit Therapeutics on 11 of the 16 factors compared between the two stocks. Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMMT vs. The Competition Export to ExcelMetricSummit TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.08B$2.42B$5.50B$9.01BDividend YieldN/A1.77%5.38%4.04%P/E Ratio-71.609.1027.6020.30Price / SalesN/A490.15369.09103.84Price / CashN/A157.0736.6357.47Price / Book45.934.638.055.68Net Income-$221.32M$31.34M$3.18B$249.13M7 Day Performance18.18%3.25%2.82%3.30%1 Month Performance24.46%6.80%3.70%5.20%1 Year Performance253.34%1.89%35.41%21.38% Summit Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMMTSummit Therapeutics2.5537 of 5 stars$24.35+7.6%$34.67+42.4%+253.3%$18.08BN/A-71.60110Trending NewsAnalyst ForecastOptions VolumeHigh Trading VolumeTAKTakeda Pharmaceutical1.4672 of 5 stars$14.72-0.3%N/A+18.7%$46.84B$4.58T66.9149,281ARGXargenex4.3225 of 5 stars$540.76-0.3%$709.18+31.1%+24.8%$33.02B$2.25B33.361,599Analyst ForecastONCBeOne Medicines3.4386 of 5 stars$257.51+4.2%$319.00+23.9%N/A$28.22B$3.81B-69.2211,000BNTXBioNTech2.3775 of 5 stars$103.01-3.3%$137.86+33.8%+37.3%$24.76B$2.98B-30.306,772TEVATeva Pharmaceutical Industries4.2372 of 5 stars$16.96+0.1%$24.44+44.1%+1.5%$19.45B$16.54B-14.7536,830ITCIIntra-Cellular Therapies0.9929 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.5889 of 5 stars$20.68-2.3%$39.17+89.4%-18.8%$13.26B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories2.8209 of 5 stars$15.31+0.5%$16.95+10.7%-0.9%$12.78B$3.81B23.2027,811Positive NewsASNDAscendis Pharma A/S3.6726 of 5 stars$175.78-0.6%$220.67+25.5%+29.7%$10.75B$393.54M-27.991,017Analyst ForecastVTRSViatris3.3111 of 5 stars$8.85-0.2%$10.40+17.5%-10.9%$10.39B$14.74B-2.7932,000 Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Viatris Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SMMT) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
